Jiuzhou Pharmacy
九洲药业
Executive Summary
Jiuzhou Pharmacy is a Zhejiang-based CDMO with strong financial performance (¥3.97B revenue, ¥631M net profit in 2024) that faces moderate BIOSECURE risk due to congressional pressure. The company demonstrates active deal-making capability through recent subsidiary drug approvals and investment activities, making it an attractive manufacturing partner for US pharma. However, BIOSECURE concerns may complicate near-term engagement strategies.
Structure: Jiuzhou Pharmacy operates through a traditional Chinese corporate structure with wholly-owned subsidiaries, as evidenced by recent drug registration announcements from subsidiaries. The company appears to have a straightforward holding company structure without complex VIE arrangements, which should simplify due diligence processes for US partners.
Latest Financials
Revenue: 3965261223.17, Net Profit: 630876705.82. Source: East Money (603456)
Period: 2024-09-30 | Source: eastmoney
Corporate Events
九洲药业：浙江九洲药业股份有限公司关于全资子公司获得药品注册证书的公告
CNINFO announcement for Jiuzhou Pharmacy (603456.SS)
九洲药业：浙江九洲药业股份有限公司关于使用部分闲置募集资金进行现金管理到期赎回的公告
CNINFO announcement for Jiuzhou Pharmacy (603456.SS)
九洲药业：浙江九洲药业股份有限公司关于开立募集资金现金管理产品专用结算账户及使用闲置募集资金进行现金管理的进展公告
CNINFO announcement for Jiuzhou Pharmacy (603456.SS)
九洲药业：浙江九洲药业股份有限公司关于使用闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告
CNINFO announcement for Jiuzhou Pharmacy (603456.SS)
九洲药业：浙江九洲药业股份有限公司关于全资子公司参与投资嘉兴隆峰创业投资合伙企业（有限合伙）的进展公告
CNINFO announcement for Jiuzhou Pharmacy (603456.SS)
Jiuzhou Pharmacy Financial Report
Revenue: 3965261223.17, Net Profit: 630876705.82. Source: East Money (603456)
BIOSECURE Risk
Company faces congressional pressure but is not formally designated under BIOSECURE Act, creating regulatory uncertainty without immediate prohibition
Key Exposures:
- •Congressional scrutiny of Chinese CDMO relationships
- •Potential future BIOSECURE designation
- •US government contract restrictions
Mitigation: No public mitigation strategies identified from available information
BD Intelligence
Therapeutic Areas:
Recent Deals: Recent subsidiary drug approvals suggest active client relationships and regulatory capabilities, plus investment in Jiaxing Longfeng venture fund indicates expansion focus
Approach: Approach with caution given BIOSECURE risks; focus on non-critical manufacturing partnerships while monitoring regulatory developments
Red Flags
- ⚠BIOSECURE congressional pressure creates regulatory uncertainty
- ⚠Limited public disclosure on key management team
- ⚠Lack of transparency on subsidiary operations and client relationships
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 6
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: HKEX annual reports, HKEX Disclosure of Interests
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.